Clinical Trials
51 trialsAndrogen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
KNIGHTS
University of Maryland, Baltimore
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
ImmunityBio, Inc.
Prostate005
University of Virginia
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
ANDARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
University of Michigan Rogel Cancer Center
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
University of Chicago
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
Thomas Jefferson University
ARPEGGIO
Brigham and Women's Hospital
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
City of Hope Medical Center
Pembro With Radiation With or Without Olaparib
University of Kentucky
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
OHSU Knight Cancer Institute
(RANGER)
University of Texas Southwestern Medical Center
Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer
The University of Hong Kong
CONVERT-HB1
Fudan University
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Case Comprehensive Cancer Center
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Bayer
OCEAN
University of Miami
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
University of Chicago
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Case Comprehensive Cancer Center
Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
RAD 1805
University of Alabama at Birmingham
HypoElect
German Oncology Center, Cyprus
RELAX
Tata Memorial Centre
HypoPro
German Oncology Center, Cyprus
STORM
University Hospital, Ghent
DIRECT
University Health Network, Toronto
Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.
Qilu Hospital of Shandong University
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
DEFINE
Ottawa Hospital Research Institute
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
Fudan University
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
ARES
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
CHAMPION
Fudan University
ENHANCE
Institut Mutualiste Montsouris
Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma
Samsung Medical Center
Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
VA Greater Los Angeles Healthcare System
ACADEMIC
University of Utah
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
Janssen Research & Development, LLC
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
University of Washington
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Dana-Farber Cancer Institute
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
Alliance for Clinical Trials in Oncology
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
The Methodist Hospital Research Institute
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
National Cancer Institute (NCI)